carteolol ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 520 51781-06-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • carteolol
  • dl-Carteolol
  • carteolol hydrochloride
  • carteolol HCl
A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
  • Molecular weight: 292.38
  • Formula: C16H24N2O3
  • CLOGP: 1.29
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 70.59
  • ALOGS: -2.84
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.49 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 88 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance) 10.10 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.70 hours Lombardo F, Berellini G, Obach RS
CL (Clearance) 10.13 mL/min/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
Vd (Volume of distribution) 4.05 L/kg Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.833 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.052 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.167 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.503 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 89.460 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 84.150 % High 1
herg hERG pIC50 4.414 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.021 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.062 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 92.550 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K7,MAPK7,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 32
kinase-selectivity-class CDK4 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.406 High 1
mh-clint Mouse hepatocyte intrinsic clearance 2.710 High 1
mppb Mouse plasma protein binding (% unbound) 86.430 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.600 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 92.370 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.758 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 92.140 % High 1
rppb Rat plasma protein binding (% unbound) 91.690 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 931.108 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 28, 1988 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 74.05 36.06 15 500 7078 90620854
Bradycardia 40.94 36.06 16 499 83831 90544101

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatitis fulminant 45.66 36.20 10 325 4949 42616051

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intraocular pressure increased 72.65 32.27 17 882 10859 110577541
Bradycardia 42.35 32.27 22 877 155495 110432905
Conjunctival hyperaemia 33.11 32.27 8 891 5823 110582577

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C07AA15 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC S01ED05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Beta blocking agents
ATC S01ED55 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Beta blocking agents
FDA MoA N0000000161 Adrenergic beta-Antagonists
FDA EPC N0000175556 beta-Adrenergic Blocker
CHEBI has role CHEBI:35530 ฮฒ-adrenergic antagonist
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:66991 sympatholytic agent
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D013565 Sympatholytics
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists

Related Drugs by ATC class:

C07AA Beta blocking agents, non-selective 13 drugs
alprenololbopindololbupranololcloranololmepindololnadololoxprenololpenbutololpindololpropranololsotaloltertatolol show all 13 →
S01ED Beta blocking agents 5 drugs
befunololbetaxolollevobunololmetipranololtimolol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Hypertensive disorder indication 38341003 DOID:10763
Open-angle glaucoma indication 84494001 DOID:1067
Angina pectoris off-label use 194828000
Complete atrioventricular block contraindication 27885002
Anaphylaxis contraindication 39579001
Sinus bradycardia contraindication 49710005
Chronic bronchitis contraindication 63480004 DOID:6132
Diabetes mellitus contraindication 73211009 DOID:9351
Heart failure contraindication 84114007 DOID:6000
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Myasthenia gravis contraindication 91637004 DOID:437
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Asthma contraindication 195967001 DOID:2841
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 9.30 WOMBAT-PK CHEMBL
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 9.20 WOMBAT-PK CHEMBL

External reference:

IDSource
4019351 VUID
N0000147523 NUI
D00599 KEGG_DRUG
51781-21-6 SECONDARY_CAS_RN
142132 RXNORM
C0007299 UMLSCUI
CHEBI:3437 CHEBI
CHEMBL839 ChEMBL_ID
DB00521 DRUGBANK_ID
CHEMBL1201002 ChEMBL_ID
D002354 MESH_DESCRIPTOR_UI
2583 PUBCHEM_CID
7142 IUPHAR_LIGAND_ID
3990 INN_ID
8NF31401XG UNII
31453 MMSL
4361 MMSL
4362 MMSL
d00708 MMSL
108544005 SNOMEDCT_US
386866004 SNOMEDCT_US
386867008 SNOMEDCT_US
4019351 VANDF
4020617 VANDF
001863 NDDF
004747 NDDF
8NF31401XG INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Carteolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 61314-238 SOLUTION 10 mg OPHTHALMIC ANDA 19 sections